NEBULA
NEBULA is a deep-tech company based in Nancy, France, pioneering physics-driven generative AI technology for drug discovery. Their dataset-free AI platform uniquely maps every dynamic 3-D conformation of therapeutic protein targets, unlocking the 80% of targets previously considered undruggable. This innovative approach enables the discovery of novel therapies for hard-to-treat cancers and CNS disorders by revealing protein shapes inaccessible to traditional methods. NEBULA partners with pharmaceutical and biotech companies worldwide through a project-based service model, accelerating drug discovery with advanced AI-driven target profiling and strategic collaborations. The company has secured significant computational resources and funding support, positioning it as a leader in AI-powered drug discovery innovation.
NEBULA
NEBULA is a deep-tech company based in Nancy, France, pioneering physics-driven generative AI technology for drug discovery. Their dataset-free AI platform uniquely maps every dynamic 3-D conformation of therapeutic protein targets, unlocking the 80% of targets previously considered undruggable. This innovative approach enables the discovery of novel therapies for hard-to-treat cancers and CNS disorders by revealing protein shapes inaccessible to traditional methods. NEBULA partners with pharmaceutical and biotech companies worldwide through a project-based service model, accelerating drug discovery with advanced AI-driven target profiling and strategic collaborations. The company has secured significant computational resources and funding support, positioning it as a leader in AI-powered drug discovery innovation.
TL;DR
Location: Nancy (Vandoeuvre-lès-Nancy), France
Founded: 2024
Tech: Physics-driven, dataset-free generative AI for 3D protein conformations
Focus: Undruggable targets; oncology and CNS disorders
Funding: Grant rounds; lead supporters include Bpifrance and Région Grand Est
Company Overview
Problem Domain
Drug discovery for challenging/undruggable protein targets with applications in oncology and neurological disease.
Founded
2024
Industry
Biotechnology
Tech Stack
Funding Track Record
Grant round reported on Dec 21, 2024; regional public support also noted (Région Grand Est).
Investor Signal
“Public grants and regional/national support (Bpifrance, Région Grand Est)”